Irbesartan Aurobindo

Irbesartan, the active ingredient in Irbesartan Aurobindo, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetic kidney disease.

GNH USA supplies Irbesartan Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Customers benefit from reliable delivery timelines and comprehensive post‑sale support.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to lower blood pressure and protect renal function.

Hypertension: reduces systolic and diastolic blood pressure in adult patients. Diabetic nephropathy: slows progression of kidney damage and reduces proteinuria in type 2 diabetes. Proteinuria: decreases urinary protein excretion in patients with renal disease.

Irbesartan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue

Serious or Rare Side Effects: - Angioedema - Hyperkalemia - Acute kidney injury

When prescribing Irbesartan, clinicians should consider several safety measures. - Monitor blood pressure regularly: ensure therapeutic targets are met and avoid excessive hypotension. - Assess renal function before and during therapy: check serum creatinine and eGFR. - Check serum potassium levels periodically: detect hyperkalemia early. - Use caution in patients with hepatic impairment: dose adjustment may be required. - Avoid use in pregnancy unless benefits outweigh risks: teratogenic potential is unknown. - Store at room temperature: keep in the original container, protect from moisture.

Irbesartan can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use may increase risk of renal impairment. - ACE inhibitors: concurrent use can cause severe hyperkalemia. - Potassium‑sparing diuretics: may lead to dangerous elevations in serum potassium.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive effect and affect renal function. - Thiazide diuretics: may enhance hypotensive response. - CYP3A4 inhibitors (e.g., ketoconazole): may increase Irbesartan plasma concentrations.